Literature DB >> 8584614

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

J Karle, L Clemmesen, L Hansen, M Andersen, J Andersen, C Fensbo, M Sloth-Nielsen, B K Skrumsager, H Lublin, J Gerlach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8584614     DOI： 10.1007/bf02246071

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  2 in total

1.  NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists.

Authors:  P H Andersen; F C Grønvald; R Hohlweg; L B Hansen; E Guddal; C Braestrup; E B Nielsen
Journal:  Eur J Pharmacol       Date:  1992-08-14       Impact factor: 4.432

2.  Reliability and validity of the positive and negative syndrome scale for schizophrenics.

Authors:  S R Kay; L A Opler; J P Lindenmayer
Journal:  Psychiatry Res       Date:  1988-01       Impact factor: 3.222
  2 in total
  9 in total

1.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?

Authors:  Anissa Abi-Dargham
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

3.  Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2006-08-30       Impact factor: 4.530

4.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

Review 5.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

6.  D1 receptor antagonists in schizophrenia.

Authors:  T R Barnes; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 8.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012

9.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.